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Introduction: Gout is the most common inflammatory arthritis worldwide and is the only type of chronic arthritis
that potentially can be ‘cured’. However, data on gout incidence, prevalence and management, assessed at multiple
time points in the same population, are sparse, particularly in Asian populations. The aim of this study was to
describe trends in the epidemiology of gout in the general population of Taiwan.
Methods: The National Health Insurance Research Database was used to identify patients with gout and to
estimate the prevalence and incidence of gout for each calendar year from 2005 to 2010. The pattern of gout
management was also examined.
Results: Of 23,371,362 beneficiaries in 2010, there were 1,458,569 prevalent and 56,595 incident cases of gout,
giving a prevalence of 6.24% (95% confidence interval (CI), 6.23% to 6.25%) and an incidence of 2.74 (95% CI, 2.72
to 2.76) per 1,000 person-years. The annual percentage change (APC) of the standardised prevalence was −0.7%
(95% CI, −1.7% to 0.3%; P = 0.14), suggesting that the prevalence of gout was essentially the same throughout the
study period. However, The APC of incidence was −13.4 (95% CI, −16.1 to −10.6) between 2005 and 2007 and −2.1
(95% CI, −10.4 to 7.1) between 2007 and 2010. Regions with the highest prevalence and incidence were eastern
coastal counties and offshore islets, where indigenous people are clustered. Among prevalent gout cases in 2010,
only 22.93% (95% CI, 22.87% to 23.00%) were prescribed urate-lowering treatment (ULT), which remained unchanged
between 2005 and 2010 at an APC of 0.0 (95% CI, −3.8 to 4.0). Uricosuric agents were more commonly prescribed than
xanthine oxidase inhibitors in Taiwan.
Conclusions: In Taiwan, 1 in 16 people have gout. Whereas the incidence has decreased recently, the prevalence remains
unchanged. Management of gout in Taiwan is poor, with only one in five affected people being treated with ULT.Introduction
Gout is the most common inflammatory arthritis and
constitutes a rising disease burden worldwide [1]. Gout
is defined by the presence of monosodium urate crystals
which deposit as a consequence of chronic elevation of
serum urate above the saturation point for urate crystal
formation. The main accepted clinical consequences of
gout are recurrent episodes of acute painful arthritis
(gout ‘attacks’), irreversible peripheral joint damage, sub-
cutaneous tophi, urate nephropathy and urolithiasis [2].* Correspondence: weiya.zhang@nottingham.ac.uk
1Division of Rheumatology, Orthopaedics and Dermatology, School of
Medicine, University of Nottingham, Academic Rheumatology, Clinical Sciences
Building, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
Full list of author information is available at the end of the article
© 2015 Kuo et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Reducing and maintaining serum urate levels below the
saturation point can prevent further crystal formation
and promote dissolution of existing urate crystals,
thereby eliminating the pathogenic agents and leading to
‘cure’. However, despite its high prevalence and relatively
well-understood pathogenesis, as well as the existence of
definitive urate-lowering therapy (ULT), gout is largely
ignored by physicians in primary care [3], who very often
treated it as an acute illness rather than as a chronic dis-
ease with major adverse consequences [4-6].
The prevalence and incidence of gout have a distinct
geographical and racial distribution [7]. In a recent gout
study in the United Kingdom, researchers found a pre-
valence of 2.49% and an incidence of 1.77 per 1,000
person-years in 2012, with both figures being higher
than earlier estimates [8]. In the United States, theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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also found a high prevalence of gout, which was 3.9%
between 2007 and 2008 [9]. Contemporary data on gout
epidemiology are relatively scant in other countries.
Taiwan is one of the countries with the highest preva-
lence of gout worldwide [10-17]. In a recent nationwide
survey (the Nutrition and Health Survey in Taiwan), re-
searchers reported gout prevalence data of 8.2% in men
and 2.3% in women in the period from 2005 to 2008
[17], which is close to the estimates for 2004 based on
information derived from the National Health Insurance
Research Database (NHIRD) [18]. In particular, Taiwanese
aborigines have a very high prevalence of gout [11,12],
which is shared with their genetically related Polynesian
cousins [19], the Māori and indigenous Oceania/Pacific
Islander populations [20]. The incidence of gout has not
been estimated in Taiwan previously, and the current
standard of care in Taiwan as reflected by the use of ULT
has not been examined to date.
Therefore, we undertook this study to examine the
prevalence and incidence of gout and the patterns of
gout management between 2005 and 2010 using the
NHIRD, which contains comprehensive information on
diagnoses, prescriptions and hospitalisations of essen-
tially the entire population in Taiwan.
Methods
The study was approved by the institutional review board
of Chang Gung Memorial Hospital (approval number
101-2178C). All data in this study were anonymised;
therefore, the need for patient consent was waived.
Source of data and study population
In this study, we used data from the NHIRD, which
contains registration files and original claims data from
approximately 28.75 million (living and deceased) benefi-
ciaries registered in the database between March 1995 and
the end of 2010. We requested from the National Health
Research Institute (the data holder of NHIRD) a tailor-
made dataset containing data of all patients with a
diagnosis of gout. Denominator data were based on the
Registry of Beneficiaries, a part of NHIRD with records of
the demographics, insurance status, residence and socio-
economic data of all beneficiaries. However, ethnicity data
were not available. Our study comprised all beneficiaries
registered continuously between 1 January 2005 and 31
December 2010.
Case definition of gout
The primary case definition of gout was having a physician-
recorded primary diagnosis of gout (International Clas-
sification of Diseases, Ninth Revision, code 274.x) at
either an outpatient or emergency visit. By searchingthe entire NHIRD, we obtained data on all patients with
gout recorded between 1995 and 2010.
Estimation of prevalence and incidence
Prevalent cases of gout were defined as individuals who
had at least one record of a primary diagnosis of gout
within the 10-year period before 1 July of each calendar
year. The denominator for prevalence estimation (the
eligible population) for each calendar year included all
individuals registered on 1 July of each calendar year.
Prevalence was calculated using the number of prevalent
cases of gout divided by the eligible population in the
specified calendar year.
Incident cases of gout defined as those patients who
had no evidence of gout or use of ULT within the 10-
year period prior to 1 January of each calendar year but
who developed gout during that year. We chose to fix
the observational period to 10 years for two reasons:
(1) The NHIRD does not have data going back further
than 10 years for beneficiaries registered in 2005, and
(2) the majority of prevalent gout cases can be identified
within a 10-year observation period, according to a pre-
vious cohort study [21]. To be eligible to be considered
as incident gout cases, beneficiaries had to have at least
a 1-year registration period prior to 1 January of each
calendar year. For the incidence of gout, we constructed
at-risk cohorts for each calendar year, comprising all in-
dividuals registered during the given calendar year who
had no history of a gout diagnosis before 1 January of
that year. Incidence was calculated using the number of
incident gout cases during a calendar year as the numer-
ator and the total person-years in an at-risk population
accumulated during that same year as the denominator.
Prevalence and incidence were calculated for 21 cities
and/or counties in Taiwan (termed regions hereinafter):
Taipei city, Taipei county, Keelung city, Taoyuan county,
Hsinchu city and county, Yilan county, Miaoli county,
Taichung city, Taichung county, Changhua county, Yunlin
county, Nantou county, Chiayi city and county, Tainan
city, Tainan county, Kaohsiung city, Kaohsiung county,
Pingtung county, Hualien county, Taitung county and off-
shore islets (Penghu, Kinmen and Lienchiang counties).
To remove the effect of different age and sex structures in
these regions, we standardised prevalence and incidence
with respect to the overall population structure of 2010.
We used choropleth maps to represent geographic varia-
tions in gout incidence and prevalence between different
regions of Taiwan.
Pattern of medication use
For each calendar year from 2005 to 2010, we ascer-
tained the proportion of prevalent gout cases in which
the patient received ULT (allopurinol, benzbromarone,
probenecid or sulfinpyrazone).
Figure 1 Age-specific prevalence (a) and incidence (b) of gout
in Taiwan in 2010. Blue: men; red: women.
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To determine the trends in prevalence, incidence and
management of gout, we calculated age- and sex-
standardised prevalence, incidence of gout and pattern
of ULT prescribing in each calendar year from 2005 to
2010 with the population structure in 2010 used as the
reference.
Statistical analysis
The 95% confidence intervals (CIs) for prevalence and in-
cidence were derived on the basis of the assumption of a
Poisson distribution for the observed number of prevalent
and incident cases. We used the Joinpoint Regression Pro-
gram (version 4.0.4; National Cancer Institute, Bethesda,
MD, USA) to estimate trends in the prevalence and inci-
dence of gout. We used the Bayesian information criterion
in the program to generate different numbers of ‘join
points’ in time when the linear trend of prevalence and in-
cidence of gout changed significantly and to determine
the best-fit data series [22]. A maximum of two join points
was used to determine statistical significance for trend.
Annual percentage changes (APCs) for each segment were
calculated. The significance level was set at 0.05. All statis-
tical analyses were performed using SAS statistical soft-
ware, version 9.3 (SAS Institute, Cary, NC, USA).
Results
Prevalence and incidence of gout in 2010
Of 23,371,362 beneficiaries (men: 49.56%) included
within the NHIRD in 2010, 1,458,569 prevalent cases of
gout were identified, giving a prevalence of 6.24% (95%
CI, 6.23% to 6.25%). Men had a significantly higher
prevalence of gout (9.34%; 95% CI, 9.32% to 9.36%) than
women (3.20%; 95% CI, 3.19% to 3.21%). Overall, the
prevalence of gout was 2.9-fold higher in men than in
women. This sex difference was observed in all age
groups, with a male-to-female ratio of 4.5 in individuals
younger than 20 years, peaking at 7.3 in those ages 30 to
34 years and then decreasing thereafter. Gout was rare
in people younger than 20 years of age, and it increased
with age, reaching a peak in the 80- to 84-year-old age
band (Figure 1a).
There were a total 20,677,590 person-years of follow-
up in 2010, during which 56,595 incident cases of gout
were identified (overall incidence, 2.74 (95% CI, 2.72 to
2.76) per 1,000 person-years). Men had a higher inci-
dence of gout (4.10 (95% CI, 4.06 to 4.14) per 1,000
person-years) than women (1.49 (95% CI, 1.47 to 1.52)
per 1,000 person-years). As shown in Figure 1b, the inci-
dence of gout in men was low in those younger than 20
years of age but increased rapidly until ages 35 to 39
years. After a relative plateau in gout incidence during
middle age, gout incidence again showed a sharp in-
crease, reaching a peak between ages 70 and 74 years. Inwomen, the incidence of gout remained low before the
age of 40, but thereafter it started to increase rapidly,
reaching a peak incidence at the age band of 80 to 84
years. The greatest male-to-female incidence ratio (6.2)
was observed in those ages 30 to 34 years, and thereafter
the difference between men and women diminished.
Prevalence and incidence of gout between 2005 and
2010
Table 1 shows the temporal trends in prevalence and in-
cidence of gout from 2005 to 2010. In general, the stan-
dardised estimates were slightly higher than the crude
ones, accounting for the fact that the population was
aging over time (refer to Additional file 1: Figure S1 for
population pyramids of Taiwan in 2005 and Additional
file 2: Figure S2 for 2010). The crude prevalence of gout
increased 5.6%, but the standardised prevalence fluc-
tuated and decreased by 3.1% over the study period. The
annual percentage change of the standardised prevalence
was −0.7 (95% CI, −1.7 to 0.3), but this was not statisti-
cally significant (P = 0.14), suggesting that the preva-
lence of gout was essentially the same throughout the
Table 1 Crude and standardised prevalence and incidence of gout from 2005 to 2010
Year Prevalence (%) Incidence (per 1,000 person-years)
N Crude Standardised Person-years Crude Standardised
Overall
2005 23,000,521 5.91 (5.90 to 5.92) 6.44 (6.43 to 6.45) 20,543,857 3.81 (3.78 to 3.84) 3.93 (3.90 to 3.96)
2006 23,127,946 6.14 (6.13 to 6.15) 6.58 (6.57 to 6.59) 20,559,914 3.21 (3.19 to 3.24) 3.29 (3.27 to 3.31)
2007 23,221,905 6.22 (6.21 to 6.23) 6.55 (6.54 to 6.56) 20,602,277 2.89 (2.86 to 2.91) 2.93 (2.91 to 2.96)
2008 23,315,001 6.27 (6.26 to 6.28) 6.49 (6.48 to 6.50) 20,645,964 2.89 (2.87 to 2.92) 2.91 (2.88 to 2.93)
2009 23,344,259 6.30 (6.29 to 6.31) 6.41 (6.40 to 6.42) 20,666,404 2.80 (2.78 to 2.82) 2.79 (2.76 to 2.81)
2010 23,371,362 6.24 (6.23 to 6.25) 6.24 (6.23 to 6.25) 20,677,590 2.74 (2.72 to 2.76) 2.74 (2.72 to 2.76)
Men
2005 11,550,180 8.35 (8.33 to 8.36) 9.01 (8.99 to 9.02) 10,048,241 5.55 (5.47 to 5.56) 5.64 (5.59 to 5.68)
2006 11,579,907 8.74 (8.72 to 8.76) 9.28 (9.27 to 9.30) 10,001,584 4.68 (4.64 to 4.72) 4.76 (4.71 to 4.80)
2007 11,598,597 8.98 (8.96 to 8.99) 9.40 (9.38 to 9.41) 9,969,808 4.26 (4.22 to 4.30) 4.30 (4.26 to 4.34)
2008 11,615,445 9.16 (9.14 to 9.18) 9.45 (9.43 to 9.47) 9,944,293 4.26 (4.22 to 4.30) 4.26 (4.22 to 4.30)
2009 11,597,439 9.32 (9.30 to 9.34) 9.47 (9.45 to 9.48) 9,907,190 4.16 (4.12 to 4.20) 4.13 (4.09 to 4.17)
2010 11,583,208 9.34 (9.32 to 9.36) 9.34 (9.32 to 9.36) 9,868,937 4.10 (4.06 to 4.14) 4.10 (4.06 to 4.14)
Women
2005 11,450,341 3.46 (3.45 to 3.47) 3.92 (3.91 to 3.93) 10,495,616 2.18 (2.15 to 2.20) 2.37 (2.34 to 2.40)
2006 11,548,039 3.54 (3.53 to 3.55) 3.92 (3.91 to 3.93) 10,558,330 1.82 (1.79 to 1.84) 1.95 (1.92 to 1.97)
2007 11,623,308 3.48 (3.47 to 3.49) 3.76 (3.75 to 3.77) 10,632,469 1.60 (1.57 to 1.62) 1.68 (1.66 to 1.71)
2008 11,699,556 3.40 (3.39 to 3.41) 3.59 (3.57 to 3.60) 10,701,671 1.62 (1.60 to 1.65) 1.67 (1.65 to 1.70)
2009 11,746,820 3.31 (3.30 to 3.32) 3.41 (3.40 to 3.42) 10,759,214 1.55 (1.52 to 1.57) 1.56 (1.54 to 1.58)
2010 11,788,157 3.20 (3.19 to 3.21) 3.20 (3.19 to 3.21) 10,808,653 1.49 (1.47 to 1.52) 1.49 (1.47 to 1.52
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nificant join point for the trend in gout prevalence. As
Figure 2a shows, the temporal trend in prevalence
among men and women was not parallel (P < 0.001).
The annual percentage change was 1.0 (95% CI, 0.1 to
1.9) in men and −4.0 (95% CI, −5.4 to −2.7) in women.
The male-to-female ratio increased slightly from 2.3 in
2005 to 2.9 in 2010.
In contrast, both the crude and standardised inci-
dences of gout declined over time during this period,
with the standardised incidence reducing by 30.3%
(Figure 2b). On average, the annual percentage change
of gout incidence was −6.7 (95% CI, −10.7 to −2.6), and
there was one join point (in 2007). The annual percentage
changes of gout incidence were −13.4 (95% CI, −16.1
to −10.6) during the period between 2005 and 2007
and −2.1 (95% CI, −10.4 to 7.1) during the period from
2007 to 2010. Figure 2b shows the trend in gout incidence
for men and women (P = 0.02), with an annual percentage
change of −8.5 (95% CI, −12.6 to −4.3) in men and −5.9
(95% CI, −9.9 to −1.8) in women. However, in both men
and women, the trends of gout incidence in the period
from 2007 to 2010 were essentially flat, with annual per-
centage changes (95% CIs) of −3.8 (−12.9 to 6.3) for men
and −1.3 (−9.6 to 7.7) for women. The male-to-femaleratio of incidence slightly increased from 2.4 in 2005 to
2.7 in 2010.
Geographic variation in 2010
Neither the prevalence nor the incidence of gout was
uniform throughout Taiwan. As shown in Figure 3, the
standardised prevalence (95% CI) of gout was highest in
the eastern coastal counties and offshore islets. The re-
gions with the lowest prevalence of gout were mostly in
the urban areas (Taipei city, Taichung city, Tainan city
and Kaohsiung city). The regional pattern of gout inci-
dence resembled that of gout prevalence, with a higher
incidence in the eastern coastal counties and offshore
islets and a lower incidence in the urban areas.
Management of gout between 2005 and 2010
Of the 1,458,569 prevalent gout cases in 2010, approxi-
mately one-third of patients had consulted for gout or
had been treated with ULT (n = 515,004; 35.31% (95%
CI, 35.23% to 35.39%)). However, only one in five preva-
lent gout cases in 2010 involved patients who were
treated with ULT (n = 334,518; 22.93% (95% CI, 22.87%
to 23.00%)). Among patients who received ULT treat-
ment, 60.08% (95% CI, 59.91% to 60.25%) received urico-
suric agents alone, 28.54% (95% CI, 28.39% to 28.69%)
Figure 2 Differences by sex in the trends of standardised
prevalence (a) and incidence (b) of gout in Taiwan between
2005 and 2010. Blue: men; red: women; green: overall).
Kuo et al. Arthritis Research & Therapy  (2015) 17:13 Page 5 of 10received a xanthine oxidase inhibitor and 11.38% (95%
CI, 11.27% to 11.49%) received both. As shown in
Figure 4a, the proportion of prevalent cases in which pa-
tients received consultations for gout or were treated by
ULT remained low during the whole study period, with
an APC of −0.9 (95% CI, −6.2 to 4.7). Similarly, the pro-
portion of patients who received ULT did not change
during this time, with an APC of 0.0 (−3.8 to 4.0).
Discussion
In this nationwide population study covering the entire
23 million population of Taiwan, about 1 in 16 residents
of Taiwan was affected by gout during the study period.
Whereas the incidence decreased, the prevalence of gout
was fairly stable over the period between 2005 and 2010.
Despite the small size of Taiwan (only 36,193 km2), both
the prevalence and incidence of gout showed marked
geographical variation. This regional variation in gout
generally coincided with the distribution of aboriginal
people in Taiwan, who primarily reside in eastern coun-
ties and rural areas. Although gout is one of the most
common chronic diseases in Taiwan, it seems that themanagement of gout remains poor, with only one-third
of people with gout receiving medical attention and only
one-fifth being given ULT. Unfortunately, this subopti-
mal care did not change over the study period, despite
the publication of national and international guidelines
on gout management during this time.
The trends of gout prevalence in Taiwan have not been
robustly examined until now. In general, surveys con-
ducted in the 1990s [10-14] reported a lower prevalence
of gout than those conducted in the 2000s [15-18]. The
National Nutrition and Health Survey in Taiwan under-
taken in the period between 1993 and 1996 found the
prevalence of gout to be 4.74% in men and 2.19% in
women [14], whereas the same survey conducted bet-
ween 2005 and 2008 found the prevalence of gout to be
8.21% in men and 2.33% in women [17]. However, these
estimates were based on patients’ self-reported gout and
were not standardised for age structure, despite use of
stratified probability sampling considering age, sex,
geographical region and ethnicity in the respective study
periods. In our present study, we found that the crude
prevalence of gout increased over time but that the age-
and sex-standardised prevalence remained stable bet-
ween 2005 and 2010. There were different trends in gout
prevalence in men and women, with the prevalence in
men reaching a plateau after 2007, whereas the preva-
lence in women continued to decrease throughout the
study period.
Several caveats should be considered before drawing
conclusion about trends in gout prevalence in Taiwan.
First, most previous studies were based on patients’ self-
reported gout [10-17], which has inherent bias. For
example, in the Atherosclerosis Risk in Communities
(ARIC) cohorts [23], only 73% of patients with gout
diagnosed by this means in 2000 also reported gout in
the follow-up questionnaire in 2003, and only 65% re-
ported gout in the 2003 and 2007 questionnaires. In a
Dutch study, researchers found that only 64% of patients
with gout self-reported it after just 6 months of follow-
up [24]. Furthermore, an earlier study found that only
44% of self-reported gout cases had this confirmed by
medical chart review and physician interview [25]. These
studies confirm significant bias connected to self-
reported gout. In our previous study conducted in 2004
[18], in which we also used the NHIRD as the primary
data source, we found a much lower prevalence of gout
(4.62%) than the estimate in 2005 in this study (5.91%).
We consider that this disparity is primarily a result of
the different lengths of observation (5 years in the pre-
vious study and 10 years in the present study) and there-
fore different degrees of identification of clinically silent
patients. It is difficult to determine to what extent a
shorter observation period might lead to underestima-
tion of prevalence. In one case series, reported in 1961,
Figure 3 Geographic variation in the prevalence (a) and incidence (b) of gout in Taiwan in 2010.
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Figure 4 Secular trends of treatment of gout in Taiwan. Proportion of prevalent gout cases in which patients received consultations for gout
or underwent urate-lowering treatment (black line), only received urate-lowering treatment (black dotted line), received uricosuric agents (red line),
received a xanthine oxidase inhibitor (blue line) or received both (green line).
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62%, from 1 to 5 years in 27%, from 6 to 10 years in 4%
and over 10 years in 7% of 614 patients [21]. Therefore,
the gout prevalence in 2004 in our previous study could
have been underestimated, because the length of the ob-
servation period was too short.
The incidence of gout has not been estimated pre-
viously in Taiwan, and incidence data in other countries
also are relatively scarce. The largest population-based
study was conducted in Rochester, MN, USA, In that
study, researchers estimated annual incidences of 0.45
per 1,000 person-years and 0.62 per 1,000 person-years
during the periods from 1977 to 1978 and 1995 to 1996,
respectively [26]. In the Framingham study in the United
States, researchers estimated an average annual inci-
dence of 1.6 and 0.2 per 1,000 person-years for men and
women, respectively, during the period between 1948
and 1980 [27], Those data are similar to the data re-
ported for men in the John Hopkins Precursors Study,
in which researchers found an incidence of 1.73 per
1,000 person-years in 1,216 male medical students over
a median of 29 years [28]. Using data from the UK
Second and Third National Studies of Morbidity in
General Practice, the overall gout incidence was estimated
to be 1.4 per 1,000 person-years in 1981 [29]. More re-
cently, Mikuls et al. used the General Practice Research
Database (GPRD) and estimated the UK all-age incidence
of gout to be 1.31 cases per 1,000 person-years in 1999
[30]. Our recent estimate of UK gout incidence in 2012,
using the same database, was 1.77 per 1,000 person-years
[8]. However, all these estimates relate to Caucasians, and
gout incidence has rarely been estimated in people ofother ethnicities. Hochberg et al. reported that the inci-
dence of gout in the period between 1958 and 1965 in
African Americans was 3.11 per 1,000 person-years, which
was 1.7-fold higher than that of Caucasians [28]. Similarly,
the ARIC study researchers reported that the gout inci-
dences in the period between 1987 and 2012 were 1.55
and 0.94 per 1,000 person-years for African American
men and Caucasian American men, respectively [31]. To
the best of our knowledge, our study is the first in which
gout incidence has been reported in an Asian population.
The incidence of gout in Taiwan was much higher than in
other countries, suggesting significant racial and geo-
graphic variation in the aetiology of gout.
The age-specific incidence of gout is rarely reported.
Data from the UK Second and Third National Studies of
Morbidity in General Practice and the Framingham
study, each undertaken in the 1980s, revealed that gout
incidence peaked around the 50s age band [27,29]. More
recently, Mikuls et al., who used the GPRD, found that
gout incidence peaked later, between the ages of 65 and
84 years [30]. In our estimates in 2012, for which we
used the same UK database, we also found a similar,
later age of peak incidence [8]. In Taiwan, we have found
that gout incidence peaks later, between the ages of 70
and 85 years. However, there was a significant difference
in age-specific incidence between men and women. In
men, we found a nonlinear distribution of age-specific
incidence of gout, wherein a marked increase in gout in-
cidence occurred in the two age bands of 20 to 39 and
50 to 69 years of age. In contrast, in women, age-specific
incidence demonstrated a near-linear increase in the in-
cidence of gout with age up to the peak incidence
Kuo et al. Arthritis Research & Therapy  (2015) 17:13 Page 8 of 10between ages 80 and 84 years. This appears unique com-
pared with previous studies on age-specific incidence
[27,29,30] in which investigators report a linear increase
in the incidence of gout with age up to the peak and then
a levelling off or slight decrease in both men and women
thereafter. Our findings echo those of a previous study by
Yu et al. which indicated that the onset of gout occurs
earlier in Taiwanese [32] than in Caucasians [33] and
Japanese [34]. The very high prevalence and incidence in
Taiwan compared to that in China [35] and Japan [36],
and the unique age-specific distribution of incidence, may
partly reflect the composition of Taiwanese residents, a
mixture of Han Chinese and indigenous people, who are
known to be very prone to gout [11,37] and who are
genetically related to Polynesians and Oceania/Pacific
Islander populations [19]. This population stratification
was also demonstrated by the regional variation in gout
prevalence and incidence because the areas with the high-
est prevalence and incidence were those with the highest
density of indigenous people with the highest genetic risk.
However, genetic factors account for just one-third of
phenotypic variation of gout in men and only one-fifth in
women [18], so environmental factors could also con-
tribute to the variable geographical distribution of gout in
Taiwan. Further studies are required to address this issue.
In our present study, we found a trend of decreasing
incidence, but generally a flattening of prevalence, dur-
ing the study period. Several explanations may account
for this finding. Firstly, relationships between incidence
and prevalence are complex and involve other factors,
such as disease duration and mortality [38]. In addition,
the static relationship between prevalence and incidence
is primarily based on a stable population with constant
parameters [39]. Our study population was not station-
ary, and both prevalence and incidence were changing.
Therefore, the change in incidence probably needs several
years to translate to changes in prevalence. Secondly, the
study period was probably too short, and longer observa-
tion would be required to measure long-term trends of
prevalence and incidence accurately. Thirdly, NHI started
in March 1995 in Taiwan, so the observation period in
2005 was 3 months short of 10 years of observation in
estimates of other calendar years. This could have led to
overestimation of incidence in 2005, the year showing the
highest incidence of gout in the study period. The results
of our study demonstrate that both prevalence and inci-
dence were stationary after 2007, a period that is less liable
to bias due to differential observation time. These results
collectively show that gout prevalence and incidence were
not increasing in the years studied, in contrast to the
global trends. Further study is required to confirm our
findings.
Regardless of the high prevalence of gout in Taiwan,
the management of the disease remains poor. We foundthat only around one-third of prevalent gout cases in-
volved patients who had contact with the health service
in relation to their gout, and only one-fourth were ac-
tually prescribed ULT. We noticed no significant change
in ULT prescription patterns during the study period,
despite the publication of Taiwanese guidelines for the
management of gout and hyperuricaemia in 2007 [40].
The poor management of gout seems to be a common
problem globally [3,8,30,41-47]. Taking the United Kingdom
as an example, the overall use of ULT in primary care
has not changed in the past two decades, with only one-
fourth to one-third of people with gout being given ULT
[8,30]. Other deviations from recommended standards of
care have also been reported in the United Kingdom
[41,42,48]. These lines of evidence underscore the lack of
knowledge and interest in gout among primary care phy-
sicians, which in turn reflects a number of varied barriers
to optimal care of patients with gout [3,49-51]. However,
in a recent proof-of-principle study conducted in the
United Kingdom, researchers found that all patients with
gout were willing to take long-term ULT once they were
given full information on gout and its treatment [52]. In
addition, these well-informed patients exhibited excellent
adherence, and nine of ten patients achieved the the-
rapeutic target at 1 year. Therefore, the essential part of
optimising care of patients with gout is likely to be phy-
sician education to improve knowledge and promote
interest in gout.
There are several limitations of the present study.
Firstly, we based our case definition on physician-
recorded diagnosis rather than according to American
College of Rheumatology criteria [53], Rome [54] classifi-
cation criteria or urate crystal identification. Secondly, we
report 10-year period prevalence rather than lifetime
prevalence, which theoretically would be higher. This is
because of the inability to identify clinically silent patients
who had no outpatient record of gout over the 10-year
period. It is difficult to determine how many patients with
gout were not included, because data on the length of
asymptomatic intercritical gout periods are sparse. On the
basis of estimates of the length of these intercritical gout
periods in the case series reported by Yu et al. [21], an
underestimation of 7% is probable. In addition to under-
estimation of prevalence, incidence would also be overesti-
mated, as some incident gout cases could have included
gout attacks prior to the 10-year observation period. We
reported geographic variations of gout prevalence and in-
cidence and attribute the significantly higher prevalence
and incidence in the eastern coastal areas and offshore
islets to aggregation of aboriginals; however, we do not
have ethnicity data to support this notion. Certainly, vari-
ation in distribution of gout risk factors may also result in
regional variation of gout prevalence and incidence. This
hypothesis requires further study to be confirmed.
Kuo et al. Arthritis Research & Therapy  (2015) 17:13 Page 9 of 10Conclusions
In this population-based study, we found a high preva-
lence and incidence of gout in Taiwan, and the regional
differences of gout prevalence and incidence were large.
Uricosuric agents are more commonly prescribed than
xanthine oxidase inhibitors. During the study period, the
prevalence of gout was stable, whereas the incidence
decreased, in Taiwan. Despite the high prevalence and
incidence of gout in Taiwan, the management of gout re-
mains poor, with only one-fourth of patients receiving
ULT, which can potentially cure gout.
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